Charles Schwab Investment Management Inc Ikena Oncology, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $527 Billion
  • Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 12,304 shares of IKNA stock, worth $17,963. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,304
Previous 12,066 1.97%
Holding current value
$17,963
Previous $20,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025
BUY
$1.53 - $1.76 $364 - $418
238 Added 1.97%
12,304 $20,000
Q2 2024

Aug 12, 2024
SELL
$1.24 - $1.82 $91,611 - $134,461
-73,880 Reduced 85.96%
12,066 $19,000
Q4 2023

Feb 06, 2024
BUY
$1.33 - $4.4 $21,561 - $71,332
16,212 Added 23.25%
85,946 $169,000
Q3 2023

Nov 08, 2023
BUY
$4.09 - $6.43 $37,120 - $58,358
9,076 Added 14.96%
69,734 $301,000
Q2 2023

Aug 09, 2023
BUY
$3.5 - $7.31 $170,072 - $355,207
48,592 Added 402.72%
60,658 $397,000
Q3 2022

Nov 14, 2022
BUY
$3.46 - $6.0 $41,748 - $72,396
12,066 New
12,066 $43,000
Q2 2022

Aug 15, 2022
SELL
$3.23 - $7.4 $215,796 - $494,394
-66,810 Closed
0 $0
Q1 2022

May 13, 2022
BUY
$5.61 - $13.85 $18,378 - $45,372
3,276 Added 5.16%
66,810 $408,000
Q4 2021

Feb 11, 2022
BUY
$10.52 - $16.96 $402,179 - $648,380
38,230 Added 151.08%
63,534 $797,000
Q3 2021

Nov 16, 2021
BUY
$9.82 - $15.23 $24,893 - $38,608
2,535 Added 11.13%
25,304 $320,000
Q2 2021

Aug 16, 2021
BUY
$13.27 - $26.0 $302,144 - $591,994
22,769 New
22,769 $320,000

Others Institutions Holding IKNA

# of Institutions
58
Shares Held
33.2M
Call Options Held
0
Put Options Held
0
View Full List

About Ikena Oncology, Inc.

IKNA Quotes by TradingView
  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $52.9M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email